Monday, Dec 18, 2017
engineered enzymes for better healthcare

Enzolve Technologies Ltd., established in 2002, is a privately owned Irish biotechnology company, which spun-out from the School of Biomolecular and Biomedical Science (University College Dublin).

Enzolve develops engineered enzymes and applies them in the healthcare and life sciences markets.

Enzolve also develops newborn screening tests NeoScreenPak for the diagnosis of inborn errors of metabolism.

Enzolve utilizes its expertise in enzyme technology for a variety of specialist applications including:

The Company is led by an expert management team that includes top scientists and leading business professionals.

Language Selection

Search

Latest News

Newborn Screening - First Steps into the marketplace
Irish technology to enable metabolic disorder screening among newborns in the developing world and remote locations... Read full article on the web Technology…

Read more...

Screen your baby’s health
Enzolve Technologies recently launched a novel newborn screening test for Phenylketonuria (PKU), an inherited metabolic disorder that results in severe mental…

Read more...

UCD campus company to begin production of newborn screening kits for international markets
Enzolve Technologies has recently secured substantial investment from Enterprise Ireland to allow them to begin immediate production of diagnostic screening kits…

Read more...